Novartis Drugs Win U.K. Backing; Bristol-Myers’s Pill Rejected

Novartis AG (NOVN)’s Tasigna and Glivec drugs won the backing of the U.K.’s health-cost agency for use against a rare blood cancer in draft treatment guidelines.

The National Institute for Health and Clinical Excellence rejected a competing product, Bristol-Myers Squibb Co. (BMY)’s Sprycel, the agency said in a statement today.

Both Tasigna and Sprycel cost more than 30,000 pounds ($47,000) a patient, the agency said. Novartis offered a price cut that allowed a recommendation for Tasigna, and the Basel, Switzerland-based company asked that the discount be kept confidential, the agency said. The guidelines also confirm a 2003 decision that Glivec is cost-effective.

The agency advises the National Health Service on which medicines represent value for money.

To contact the reporter on this story: Kristen Hallam in London at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.